1-1 of 1
Barbara Dewaele, PhD
Close
Sort by
Journal Articles

Ponatinib Is Active Against the CUX1-FGFR1 Fusion Kinase and Against Imatinib Resistance Mutations of the FIP1L1-PDGFRα Fusion Kinase and of KIT,

Els Lierman, PhD, Sanne Smits, Jan Cools, PhD, Barbara Dewaele, PhD, Maria Debiec-Rychter, MD PhD, Peter Vandenberghe, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3848.
https://doi.org/10.1182/blood.V118.21.3848.3848
Published: 2011